Characteristics | Number (%) or mean (range) | |||
---|---|---|---|---|
 | HC (n= 30) | AAV | ||
 |  | Remission ( n = 37) | Active a ( n = 5) | Active b ( n = 18) |
Male | 17 (57) | 25 (68) | 3 (60) | 14 (78) |
Age (years) | 45 (28-64) | 57 (26-84) | 58 (47-68) | 58 (32-81) |
Diagnosis | Â | Â | Â | Â |
GPA | Â | 26 | 4 | 13 |
MPA | Â | 9 | 1 | 5 |
NCGN | Â | 2 | 0 | 0 |
ANCA-specificity | Â | Â | Â | Â |
PR3 | Â | 24 (65) | 4 (80) | 13 (72) |
MPO | Â | 13 (35) | 1 (20) | 5 (28) |
Organ involvement | Â | Â | Â | Â |
ENT | Â | 0 | 4 (80) | 5 (28) |
Eye | Â | 0 | 1 (20) | 4 (22) |
Lung | Â | 0 | 4 (80) | 8 (44) |
Kidney | Â | 0 | 2 (40) | 13 (72) |
Skin | Â | 0 | 1 (20) | 0 |
Nervous system | Â | 0 | 1 (20) | 2 (11) |
BVAS, median (range) | Â | 0 | 14.8 (6-26) | 17.5 (6-33) |
Treatment | Â | Â | Â | Â |
MMF | Â | 0 | 1 (20) | 3 (17) |
CYC | Â | 0 | 4 (80) | 11 (61) |
Prednisolon | Â | 0 | 4 (80) | 16 (89) |